Healthpeak Properties Gains on Higher FFO Guidance

Healthpeak Properties is showing that a monthly dividend can still attract buyers even as interest-rate pressure keeps the broader REIT sector under strain.
The healthcare real estate investment trust has become a standout among S&P 500 income names this year, with its shares up 27.5% in 2026 even after recent volatility. At a recent price of $20.42, Healthpeak’s monthly payout of a little more than 10 cents a share works out to about $1.22 a year, a yield near 6% — a level that remains compelling for investors seeking cash flow in a market where bond yields have risen and many REITs have struggled.
The key reason the stock has outperformed is not just income, but improving fundamentals. Healthpeak reported first-quarter earnings per share of 28 cents, quadruple the 6-cent analyst forecast, on revenue of $739 million, topping estimates by 7.5%. Management then raised full-year funds from operations guidance, first to $1.71 to $1.75 per share and later, after second-quarter results, to $1.73 to $1.77. For REIT investors, higher FFO guidance matters more than headline earnings because it signals the company’s ability to cover distributions and sustain growth in property cash flow.
That combination has helped Healthpeak stand apart from a sector that has been battered by financing costs. REITs typically borrow heavily to expand, so rising rates hit them twice: they raise debt-service costs and make income securities less attractive relative to Treasuries and cash. Recent pressure across the sector has also spilled into names such as Realty Income, another monthly payer. But Healthpeak’s healthcare focus gives it a longer-duration demand story that is less exposed to consumer spending cycles and more tied to structural aging trends.
The company owns hundreds of healthcare discovery and delivery assets, including outpatient centers, labs and senior housing properties, positioning it to benefit from rising demand for medical real estate. That demand backdrop is especially important now, as healthcare REITs are increasingly being judged not only on yield, but on whether they can grow occupancy, rents and cash flow fast enough to offset funding costs.
Still, the stock is not priced as a clean, one-way trade. Of the 22 analysts covering Healthpeak, 14 rate it a hold, while three call it a strong buy and five a buy. The average target price is $23, only modestly above the current level, suggesting the market has already acknowledged much of the improvement. The recent rally also means income investors are buying a stronger business, but not necessarily a cheap one.
The bigger question for investors is whether Healthpeak can keep pairing yield with capital appreciation if rates stay elevated. If management continues to raise FFO guidance and healthcare property demand remains resilient, the stock can keep attracting dividend seekers. If financing costs climb further or the REIT sector loses another leg of support, the income story may remain intact even if the share price stalls.
| Entity | Gains | Losses |
|---|---|---|
| Healthpeak Properties | ▲Higher FFO guidance | ▼Rate-sensitive valuation pressure |
| Income investors | ▲Monthly cash flow | ▼Limited upside if rates rise |
| Bondholders / Treasuries | ▲Competitive yield appeal | ▼Share of yield-seeking capital |
| Broader REIT sector | ▲Healthcare demand tailwind | ▼Higher borrowing costs |